Autoimmunpankreatitis und IgG4-assoziierte Erkrankungen

Die häufigste Manifestation IgG4-assoziierter Erkrankungen ist die Autoimmunpankreatitis Typ 1 (AIP1), die klinisch mitunter schwer von einem lokalisierten Pankreaskarzinom zu unterscheiden ist. In diesem Artikel werden praxisrelevante Aspekte der Erkrankungen hervorgehoben, begleitet von einem klinischen Beispiel aus der Universitätsklinik Ulm. Der Schwerpunkt liegt dabei aufgrund der Häufigkeit auf der Autoimmunpankreatitis Typ 1.

Schlüsselwörter

IgG4-assoziierte Erkrankungen - Autoimmunpankreatitis - AIP1 - AIP2 - Organbefall - Aortitis - retroperitoneale Fibrose

• Literatur

• 1 Overbeek KA, Poulsen JL, Lanzillotta M. et al. Type 1 Autoimmune Pancreatitis in Europe: Clinical Profile and Response to Treatment. Gut 2024; 22: 994-1004
• 2 Wallace ZS, Miles G, Smolkina E. et al. Incidence, prevalence, and mortality of IgG4-related disease in the USA: a claims-based analysis of commercially insured adults. Ann Rheum Dis 2023; 82: 957-962
• 3 Uchida K, Okazaki K. Current status of type 1 (IgG4-related) autoimmune pancreatitis. J Gastroenterol 2022; 57: 695-708
• 4 Davies AM, Sutton BJ. Human IgG4: a structural perspective. Immunol Rev 2015; 268: 139-159
• 5 Wallace ZS, Zhang Y, Perugino CA. ACR/EULAR IgG4-RD Classification Criteria Committee. et al. Clinical phenotypes of IgG4-related disease: an analysis of two international cross-sectional cohorts. Ann Rheum Dis 2019; 78: 406-412
• 6 Carruthers MN, Khosroshahi A, Augustin T. et al. The diagnostic utility of serum IgG4 concentrations in IgG4-related disease. Ann Rheum Dis 2015; 74: 14-18
• 7 Xu WL, Ling YC, Wang ZK, Deng F. Diagnostic performance of serum IgG4 level for IgG4-related disease: a meta-analysis. Sci Rep 2016; 6: 32035
• 8 Mattoo H, Mahajan VS, Della-Torre E. et al. De novo oligoclonal expansions of circulating plasmablasts in active and relapsing IgG4-related disease. J Allergy Clin Immunol 2014; 134: 679-687
• 9 Takahashi M, Fujinaga Y, Notohara K. Working Group Members of The Research Program on Intractable Diseases from the Ministry of Labor, Welfare of Japan. et al. Diagnostic imaging guide for autoimmune pancreatitis. Jpn J Radiol 2020; 38: 591-612
• 10 Wallace ZS, Naden RP, Chari S. American College of Rheumatology/European League Against, Rheumatism IgG4-Related Disease Classification Criteria Working Group. et al. The 2019 American College of Rheumatology/European League Against Rheumatism Classification Criteria for IgG4-Related Disease. Arthritis Rheumatol 2020; 72: 7-19
• 11 Shimosegawa T, Chari ST, Frulloni L. International Association of Pancreatology. et al. International consensus diagnostic criteria for autoimmune pancreatitis: guidelines of the International Association of Pancreatology. Pancreas 2011; 40: 352-358
• 12 Chari ST. Diagnosis of autoimmune pancreatitis using its five cardinal features: introducing the Mayo Clinic’s HISORt criteria. J Gastroenterol 2007; 42 (Suppl. 18) 39-41
• 13 Schneider A, Michaely H, Rückert F. et al. Diagnosing autoimmune pancreatitis with the Unifying-Autoimmune-Pancreatitis-Criteria. Pancreatology 2017; 17: 381-394
• 14 Khosroshahi A, Wallace ZS, Crowe JL. Second International Symposium on IgG4-Related Disease. et al. International Consensus Guidance Statement on the Management and Treatment of IgG4-Related Disease. Arthritis Rheumatol 2015; 67: 1688-1699
• 15 Okazaki K, Chari ST, Frulloni L. et al. International consensus for the treatment of autoimmune pancreatitis. Pancreatology 2017; 17: 1-6
• 16 Hart PA, Topazian MD, Witzig TE. et al. Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: the Mayo Clinic experience. Gut 2013; 62: 1607-1615
• 17 Buch MH, Smolen JS, Betteridge N. et al. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 2011; 70: 909-920
• 18 Perugino C, Culver EL, Khosroshahi A. et al. Efficacy and Safety of Inebilizumab in IgG4-Related Disease: Protocol for a Randomized Controlled Trial. Rheumatol Ther 2023; 10: 1795-1808
• 19 Carruthers MN, Stone JH, Deshpande V. et al. Development of an IgG4-RD Responder Index. Int J Rheumatol 2012; 2012: 259408
• 20 Kamisawa T, Shimosegawa T, Okazaki K. et al. Standard steroid treatment for autoimmune pancreatitis. Gut 2009; 58: 1504-1507
• 21 Sano T, Kikuta K, Takikawa T. et al. The M-ANNHEIM-AiP-Activity-Score is useful for predicting relapse in patients with type 1 autoimmune pancreatitis. Pancreatology 2023; 23: 112-119
• 22 Ikeura T, Miyoshi H, Shimatani M. et al. Long-term outcomes of autoimmune pancreatitis. World J Gastroenterol 2016; 22: 7760-7766
• 23 Evans RDR, Cargill T, Goodchild G. et al. Clinical manifestations and long-term outcomes of IgG4-related kidney and retroperitoneal involvement in a United Kingdom IgG4-related disease cohort. Kidney Int Rep 2018; 4: 48-58